Lumira Ventures — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin S Eisenfrats(Executive Officer, Director, Promoter)Kevin Eisenfrats(Co-Founder and CEO)John Herr(Co-Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)
Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture Capital+14 more
Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.
HardwareHealthtechMedical Devices
Co-investorsFoothill VenturesShangBay Capital LLCUS Venture PartnersAmzak Health
SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.
HardwareHealthtechMedical Devices
Jeremy Brown(Co-Founder & CTO)inMatt Mallay(Co-Founder & Sr. Dir. R&D)inAndre Bezanson(Co-Founder & Dir. R&D)inEli Vlaisavljevich(Co-Founder)inRick Balys(Co-Founder)inNeil Barman(Chief Executive Officer)in
Co-investorsAmzak HealthInvest Nova Scotia
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.